Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
03:19:05 EDT Mon 23 Jun 2025
Enter Symbol
or Name
USA
CA



Forgot password?
Trouble logging in?
Login ID:
Password:
Save

Q:KPTI - KARYOPHARM THERAPEUTICS INC - https://www.karyopharm.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
KPTI - Q8.04.18·5.740.14.38-0.06-1.423.7952104.56  4.56  4.270117.40  3.51Jun 20Jun 0315 min RT 2¢

Recent Trades - Last 10 of 210
Time ETExPriceChangeVolume
16:04:05Q4.38-0.061
16:00:13Q4.38-0.0622
16:00:13Q4.38-0.063
16:00:13Q4.38-0.06107
16:00:13Q4.38-0.061
16:00:03Q4.38-0.0615
16:00:03Q4.38-0.065
16:00:03Q4.38-0.061,254
16:00:03Q4.38-0.069
16:00:03Q4.38-0.0692

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2025-06-03 08:00U:KPTINews ReleaseKaryopharm to Present at the Jefferies Global Healthcare Conference
2025-06-02 16:05U:KPTINews ReleaseKaryopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2025-05-19 07:00U:KPTINews ReleaseKaryopharm to Participate at the 2025 RBC Capital Markets Global Healthcare Conference
2025-05-14 09:31U:KPTINews ReleaseKaryopharm Announces Poster Presentation on Selinexor in Myelofibrosis at the 2025 European Hematology Association Annual Meeting
2025-05-12 16:05U:KPTINews ReleaseKaryopharm Reports First Quarter 2025 Financial Results and Announces New Data in Myelofibrosis that Further Suggests Selinexor May Lead to Meaningful Spleen Volume Reduction, Symptom Improvement, Hemoglobin Stabilization and Disease Modification
2025-05-08 16:05U:KPTINews ReleaseKaryopharm to Report First Quarter 2025 Financial Results on May 12, 2025
2025-05-01 16:05U:KPTINews ReleaseKaryopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2025-04-01 16:05U:KPTINews ReleaseKaryopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2025-03-03 16:05U:KPTINews ReleaseKaryopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2025-02-24 08:40U:KPTINews ReleaseKaryopharm Announces 1-for-15 Reverse Stock Split
2025-02-19 07:30U:KPTINews ReleaseKaryopharm Reports Fourth Quarter and Full Year 2024 Financial Results, Announces Update to Phase 3 XPORT-EC-042 Trial and Highlights Recent Company Progress
2025-02-12 07:00U:KPTINews ReleaseKaryopharm to Report Fourth Quarter and Full Year 2024 Financial Results on February 19, 2025
2025-02-03 16:05U:KPTINews ReleaseKaryopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2025-01-13 08:30U:KPTINews ReleaseKaryopharm Announces Preliminary Unaudited 2024 Revenue and 2025 Objectives
2025-01-02 16:05U:KPTINews ReleaseKaryopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2025-01-02 07:00U:KPTINews ReleaseKaryopharm Announces the Appointment of Lori Macomber as Chief Financial Officer
2024-12-09 08:00U:KPTINews ReleaseKaryopharm Announces the Appointment of Brendan Strong as Senior Vice President of Investor Relations and Corporate Communications
2024-12-03 07:00U:KPTINews ReleaseKaryopharm Therapeutics Provides Endometrial Cancer Program Update
2024-12-02 07:00U:KPTINews ReleaseKaryopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-11-25 07:00U:KPTINews ReleaseKaryopharm to Participate at the Piper Sandler 36th Annual Healthcare Conference